Emerging Issues in AAV-Mediated In Vivo Gene Therapy.

about

The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses.The Pharmacology of Gene and Cell Therapy.Pompe disease: how to solve many problems with one solution

P2860

Q52584646-9947DFD6-832A-427D-90BC-AF29585F95B4 Q55099698-60D6CE7C-4DC9-4F65-87E3-883342CA35A3 Q58804800-3720AEA5-8C3B-4FAD-AD51-61BE6D30181A

P2860

Emerging Issues in AAV-Mediated In Vivo Gene Therapy.

Item

http://www.wikidata.org/entity/Q47554736

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Emerging Issues in AAV-Mediated In Vivo Gene Therapy.

@en

Emerging Issues in AAV-Mediated In Vivo Gene Therapy.

@nl

type

Item

label

Emerging Issues in AAV-Mediated In Vivo Gene Therapy.

@en

Emerging Issues in AAV-Mediated In Vivo Gene Therapy.

@nl

prefLabel

Emerging Issues in AAV-Mediated In Vivo Gene Therapy.

@en

Emerging Issues in AAV-Mediated In Vivo Gene Therapy.

@nl

P1476

Emerging Issues in AAV-Mediated In Vivo Gene Therapy.

@en

P2093

Federico Mingozzi

http://www.w3.org/2001/XMLSchema#string

Giuseppe Ronzitti

http://www.w3.org/2001/XMLSchema#string

P2860

Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps.

Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy

A viral assembly factor promotes AAV2 capsid formation in the nucleolus

Body Length and Organ Weights of Infants and Children: A Study of the Body Length and Normal Weights of the More Important Vital Organs of the Body between Birth and Twelve Years of Age

Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions

In vivo genome editing restores haemostasis in a mouse model of haemophilia

Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation

Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response

Rescue of bilirubin-induced neonatal lethality in a mouse model of Crigler-Najjar syndrome type I by AAV9-mediated gene transfer

Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy

P304

87-104

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.OMTM.2017.11.007

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Pasqualina Colella

P577

2017-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29326962

http://www.w3.org/2001/XMLSchema#string

P921

gene therapy

P932

5758940

http://www.w3.org/2001/XMLSchema#string

Emerging Issues in AAV-Mediated In Vivo Gene Therapy.

about

P2860

P2860

Emerging Issues in AAV-Mediated In Vivo Gene Therapy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P50

P577

P698

P921

P932